İlaçlar

Her ilaç için bir sayfa. Etki büyüklükleri, deneme tasarımları ve ölçümlerin yapıldığı popülasyonlar.

Peptide

Semaglutide

STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.

Dual agonist

Tirzepatide

SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.

Oral

Oral GLP-1

Oral semaglutide and orforglipron — the same mechanism without the injection.

Also from us

Tools and books we publish that are relevant to this page. These are ours — we say so rather than presenting them as neutral picks.

App ⏱️ LyteFast
Intermittent fasting timer with an evidence-based coach
App 🍽️ Litely
Food tracker and fasting timer for people who hate fasting apps
App 🐟 Sardines Fasting
Structured fasting protocols with a food-first approach
App 🥦 Fiberlism
Fibre tracking, because almost nobody hits the target
App 📷 SkinnyScan
Scan any meal for calories, macros and an A–E health grade
Book 📘 The Sardines Fasting Method
A food-first take on intermittent fasting: what to eat in the window, not just when to close it.
Book 📓 The SkinnyScan Guide
Decoding nutrition labels and the marketing built on top of them.
App 🌙 BioClock Sleep
Circadian-aware sleep and light tracking

İlgili okumalar

Fasting Evidence

Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.

Metabolism Review

Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.

Weight Loss Evidence

Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.

Sleep Evidence

Sleep, circadian rhythm and the wearables that claim to measure both.

Bu sayfa otomatik olarak İngilizce'den çevrilmiştir. Alıntılar ve sayılar değişmemiştir. Herhangi bir şey garip görünüyorsa İngilizce orijinalini okuyun. İngilizce orijinalini oku